159 related articles for article (PubMed ID: 31793049)
1. Livedoid vasculopathy in Koreans: clinical features and response to rivaroxaban treatment.
Lee JS; Cho S
J Eur Acad Dermatol Venereol; 2020 Apr; 34(4):e176-e178. PubMed ID: 31793049
[No Abstract] [Full Text] [Related]
2. Prevention of livedoid vasculopathy recurrence by prolonged administration of rivaroxaban.
Drerup C; Goerge T
J Eur Acad Dermatol Venereol; 2017 Dec; 31(12):e532. PubMed ID: 28609556
[No Abstract] [Full Text] [Related]
3. Treatment of Livedoid Vasculopathy With Rivaroxaban: A Potential Use of New Oral Anticoagulants for Dermatologists.
Jiménez-Gallo D; Villegas-Romero I; Rodríguez-Mateos ME; Linares-Barrios M
Actas Dermosifiliogr (Engl Ed); 2018 Apr; 109(3):278-281. PubMed ID: 29074145
[No Abstract] [Full Text] [Related]
4. Characteristics, risk factors and treatment reality in livedoid vasculopathy - a multicentre analysis.
Weishaupt C; Strölin A; Kahle B; Kreuter A; Schneider SW; Gerss J; Eveslage M; Drabik A; Goerge T
J Eur Acad Dermatol Venereol; 2019 Sep; 33(9):1784-1791. PubMed ID: 31009111
[TBL] [Abstract][Full Text] [Related]
5. Excellent Long-term Clinical Response to Rivaroxaban in Livedoid Vasculopathy: A Retrospective Study.
Morgado-Carrasco D; Ibaceta J; Iranzo P; Bosch-Amate X; Mascaró-Galy JM
Actas Dermosifiliogr; 2023 Feb; 114(2):183-185. PubMed ID: 36115384
[No Abstract] [Full Text] [Related]
6. Rivaroxaban prevents painful cutaneous infarctions in livedoid vasculopathy.
Kerk N; Drabik A; Luger TA; Schneider SW; Goerge T
Br J Dermatol; 2013 Apr; 168(4):898-9. PubMed ID: 23106384
[No Abstract] [Full Text] [Related]
7. Rapid remission of severe pain from livedoid vasculopathy by apixaban.
Yamaguchi Y; Nakazato S; Izumi K; Ieko M; Nomura T; Shimizu H
J Eur Acad Dermatol Venereol; 2017 Jan; 31(1):e45-e46. PubMed ID: 27166520
[No Abstract] [Full Text] [Related]
8. Anticoagulation with rivaroxaban for livedoid vasculopathy (RILIVA): a multicentre, single-arm, open-label, phase 2a, proof-of-concept trial.
Weishaupt C; Strölin A; Kahle B; Kreuter A; Schneider SW; Gerss J; Eveslage M; Drabik A; Goerge T
Lancet Haematol; 2016 Feb; 3(2):e72-9. PubMed ID: 26853646
[TBL] [Abstract][Full Text] [Related]
9. Case series of recalcitrant livedoid vasculopathy treated with rivaroxaban.
Lee JM; Kim IH
Clin Exp Dermatol; 2016 Jul; 41(5):559-61. PubMed ID: 26993107
[No Abstract] [Full Text] [Related]
10. Chronic leg ulcerations associated with livedoid vasculopathy successfully treated with rivaroxaban.
Miguel D; Elsner P; Goetze S
Clin Exp Dermatol; 2020 Jan; 45(1):120-122. PubMed ID: 30767258
[No Abstract] [Full Text] [Related]
11. Efficacy of new low-dose oral anticoagulants in recalcitrant livedoid vasculopathy.
Furukawa F; Mizawa M; Makino T; Shimizu T
BMJ Case Rep; 2017 Jul; 2017():. PubMed ID: 28739563
[TBL] [Abstract][Full Text] [Related]
12. Response of livedoid vasculopathy to rivaroxaban.
Winchester DS; Drage LA; Davis MD
Br J Dermatol; 2015 Apr; 172(4):1148-50. PubMed ID: 25255997
[No Abstract] [Full Text] [Related]
13. Livedoid Vasculopathy Presenting in a Patient With Sickle Cell Disease.
Reagin H; Marks E; Weis S; Susa J
Am J Dermatopathol; 2018 Sep; 40(9):682-685. PubMed ID: 29533274
[TBL] [Abstract][Full Text] [Related]
14. Treatment of livedoid vasculopathy with alprostadil (PGE-1): case report and review of published literature.
Mofarrah R; Aberer W; Aberer E
J Eur Acad Dermatol Venereol; 2013 Feb; 27(2):e252-4. PubMed ID: 22364635
[No Abstract] [Full Text] [Related]
15. The management of livedoid vasculopathy focused on direct oral anticoagulants (DOACs): four case reports successfully treated with rivaroxaban.
Franco Marques G; Criado PR; Alves Batista Morita TC; Cajas García MS
Int J Dermatol; 2018 Jun; 57(6):732-741. PubMed ID: 29663354
[TBL] [Abstract][Full Text] [Related]
16. Rivaroxaban for heparin-induced thrombocytopenia: adding to the evidence.
Ong SY; Chin YA; Than H; Tan CW; Yap ES; Wong WH; Ng HJ
Ann Hematol; 2017 Mar; 96(3):525-527. PubMed ID: 27822611
[No Abstract] [Full Text] [Related]
17. Apixaban and rivaroxaban in patients with cerebral venous thrombosis.
Covut F; Kewan T; Perez O; Flores M; Haddad A; Daw H
Thromb Res; 2019 Jan; 173():77-78. PubMed ID: 30481600
[No Abstract] [Full Text] [Related]
18. Intravenous immunoglobulin in resistant livedoid vasculopathy: Analysis of a case series.
Ozden MG; Ozdemir H; Şenturk N
Dermatol Ther; 2020 Mar; 33(2):e13229. PubMed ID: 31965687
[TBL] [Abstract][Full Text] [Related]
19. Livedoid Vasculopathy: A French Observational Study Including Therapeutic Options.
Gardette E; Moguelet P; Bouaziz JD; Lipsker D; Dereure O; Le Pelletier F; Lok C; Maisonobe T; Bessis D; Conard J; Francès C; Barete S
Acta Derm Venereol; 2018 Oct; 98(9):842-847. PubMed ID: 29738044
[TBL] [Abstract][Full Text] [Related]
20. Livedoid vasculopathy; favorable clinical response with low dose warfarin.
Nakamura S; Kishibe M; Nishi K; Hashimoto Y; Takeda K; Mizumoto T; Iizuka H
Eur J Dermatol; 2011; 21(6):1011-2. PubMed ID: 21914587
[No Abstract] [Full Text] [Related]
[Next] [New Search]
